Contact
searchSearch
HMP Global
Login

Psychedelics News

fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Jolynn Tumolo
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
Meagan Thistle
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
News
Microdosing Associated With Increased Mindfulness, Lower Neuroticism in ADHD Patients
11/28/2023
Tom Valentino
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers...
11/28/2023
Psych Congress Network
News
Compass Pathways Initiates Phase 3 Study of Psilocybin for Treatment-Resistant Depression
11/27/2023
Tom Valentino
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently...
11/27/2023
Psych Congress Network
Christopher Nicholas, PhD
News
Psychedelics Show Potential to Improve SUD Treatment Outcomes
10/31/2023
Tom Valentino
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths...
10/31/2023
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use